First RCT: vaporized THC+CBD was superior to placebo for acute migraine, with effects lasting 48 hours | Research

The takeaway

In the first randomized, placebo-controlled trial of cannabis for acute migraine, vaporized THC+CBD was significantly superior to placebo for pain relief (67% vs 47%), pain freedom (35% vs 16%), and most bothersome symptom freedom (60% vs 35%) at 2 hours, with benefits sustained through 48 hours.

Migraine sufferers, neurologists, and anyone interested in evidence-based cannabis therapeutics.

67% pain relief at 2 hours with THC+CBD vs 47% placebo; benefits sustained through 48 hours

What the researchers found

THC+CBD (6% THC + 11% CBD) was superior to placebo for pain relief (67.2% vs 46.6%, OR 2.85), pain freedom (34.5% vs 15.5%, OR 3.30), and most bothersome symptom freedom (60.3% vs 34.5%, OR 3.32) at 2 hours, with sustained benefits at 24 and 48 hours. THC-dominant was superior for pain relief only (68.9% vs 46.6%, OR 3.14). CBD-dominant was not superior to placebo for any primary outcome. No serious adverse events.

Why it matters

This is the first ever randomized controlled trial of cannabis for acute migraine. Migraine affects over 1 billion people globally, and current treatments fail for many patients. The finding that THC+CBD achieved 67% pain relief at 2 hours (comparable to triptans) with sustained 48-hour benefits and no serious adverse events is a landmark result.

The numbers in context

92 participants, 247 attacks treated. THC+CBD vs placebo at 2h: pain relief 67.2% vs 46.6% (OR 2.85, p=0.016), pain freedom 34.5% vs 15.5% (OR 3.30, p=0.017), MBS freedom 60.3% vs 34.5% (OR 3.32, p=0.005). THC alone: pain relief 68.9% vs 46.6% (OR 3.14, p=0.008). CBD alone: not superior to placebo. No serious adverse events.

How the study worked

Randomized, double-blind, placebo-controlled, crossover trial. 92 adults with migraine treated up to four attacks, one each with: (1) 6% THC, (2) 11% CBD, (3) 6% THC + 11% CBD, or (4) placebo cannabis flower. Minimum 1-week washout between attacks. 247 migraine attacks treated total. Primary endpoint: pain relief at 2 hours.

What this study cannot tell us

Vaporization limits generalizability to patients willing and able to inhale. The placebo response was substantial (47%). Crossover design with up to four attacks per person means some variability in migraine characteristics. Sample size of 92 was modest. Only acute treatment was studied, not preventive use.

How to read the evidence

Randomized, double-blind, placebo-controlled, crossover trial with four treatment arms, published in Headache, representing the highest quality clinical evidence to date for cannabis in migraine.

When this study was published

Published in 2026.

The bigger picture

The finding that CBD alone did not work for migraine while THC+CBD did suggests THC is the primary analgesic component, with CBD potentially contributing to the combination effect. This has practical implications for patients in jurisdictions where THC is restricted. The sustained benefits at 24 and 48 hours suggest cannabinoids may address mechanisms beyond acute pain, possibly including neuroinflammation.

Questions still open

Would oral or sublingual cannabinoid formulations show similar efficacy? Could cannabis be used as rescue therapy for triptan non-responders? What is the optimal THC:CBD ratio for migraine? Would regular use lead to tolerance?

Common questions

Does cannabis work for migraines?

This first randomized trial found that vaporized THC+CBD was significantly better than placebo, with 67% achieving pain relief at 2 hours. THC alone helped with pain relief but not complete pain freedom. CBD alone did not work.

How does this compare to standard migraine treatments?

The 67% pain relief rate at 2 hours is comparable to some triptans. The sustained benefits at 24 and 48 hours are notable, as some acute migraine treatments show headache recurrence within 24 hours.

Were there side effects?

No serious adverse events were reported. The study used vaporized cannabis flower, which produces rapid onset effects but may involve respiratory exposure.

Read the original research

Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.

Headache, 66(2), 365-376

View on PubMed ↗Publisher’s paper ↗

Citation

Schuster, Nathaniel M; Wallace, Mark S; Marcotte, Thomas D; Buse, Dawn C; Lee, Euyhyun; Liu, Lin; Sexton, Michelle. (2026). Vaporized cannabis versus placebo for acute migraine: A randomized, double-blind, placebo-controlled crossover trial.. Headache, 66(2), 365-376. https://doi.org/10.1111/head.70025